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Leukocyte recruitment to sites of infection or tissue damage plays a crucial role for the
innate immune response. Chemokine-dependent signaling in immune cells is a very impor-
tant mechanism leading to integrin activation and leukocyte recruitment. CXC chemokine
receptor 2 (CXCR2) is a prominent chemokine receptor on neutrophils. During the last years,
several studies were performed investigating the role of CXCR2 in different diseases. Until
now, many CXCR2 inhibitors are tested in animal models and clinical trials and promising
results were obtained. This review gives an overview of the structure of CXCR2 and the
signaling pathways that are activated following CXCR2 stimulation. We discuss in detail
the role of this chemokine receptor in different disease models including acute lung injury,
COPD, sepsis, and ischemia-reperfusion-injury. Furthermore, this review summarizes the
results of clinical trials which used CXCR2 inhibitors.
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INTRODUCTION
Inflammation is a defense reaction caused by infection or tissue
damage. The aim of this process is to eliminate the inflammatory
stimulus and protect the surrounding tissue from further dam-
age making it necessary for the survival of the host. A defect in
this system can severely affect the integrity of the organism and
may be fatal. This is demonstrated in patients with hereditary
or acquired immune deficiency. Neutrophil depletion can have
detrimental effects in some disease models, but is beneficial in oth-
ers (Henson and Johnston Jr., 1987; Weiss, 1989). The reduction
of neutrophil recruitment in disease models elicited by bacte-
ria resulted in decreased bacterial clearance and reduced survival
(Craig et al., 2009). The same observation can be made in patients
suffering from leukocyte adhesion deficiency (LAD). This disease
is characterized by a defect in leukocyte extravasation, resulting
in an inappropriate inflammatory response to injury or infection
(Etzioni, 2010). Patients with this disease suffer from recurrent
bacterial infections and have a reduced life expectancy (Etzioni,
2010).
Neutrophil granulocytes represent an important cellular com-
ponent of the innate immune system and are recruited following
an inflammatory stimulus in a coordinated sequence of events into
inflamed tissue (Ley et al., 2007). The leukocyte recruitment cas-
cade consists of different steps including capturing, rolling, slow
rolling, adhesion, crawling, and other activation events prior trans-
migration (Ley et al., 2007). Leukocyte capturing and rolling is
mediated by selectins (Ley et al., 2007), whereas slow leukocyte
rolling and adhesion is predominantly mediated by integrins inter-
acting with their ligands expressed on endothelial cells. Integrins
are members of a large family of conserved adhesion receptors,
which occur in a low affinity conformational state on circulat-
ing leukocytes. Selectin and immunoreceptor engagement and
chemokine binding to their receptors activate signaling pathways
leading to the activation of integrins (inside-out signaling). During
adhesion, engaged integrins can signal into leukocytes (outside-in
signaling), which stabilizes adhesion and initiates transmigration.
The activation of neutrophils during the recruitment process is
mediated by different mediators including selectins, chemokines,
and integrin-mediated outside-in signaling.
Selectin engagement activates different signaling pathways
leading to tyrosine phosphorylation, cytoskeletal rearrangement,
β2-integrin activation, cytokine secretion, and transcriptional acti-
vation. It has been shown that P- and E-selectin engagement
induces β2-integrin activation and reduces the rolling velocity on
P-selectin/E-selectin and ICAM-1 (Zarbock et al., 2007b; Kuwano
et al., 2010). Selectin engagement induces LFA-1 activation in a
Syk (spleen tyrosine kinase)-dependent manner (Zarbock et al.,
2007b). E-selectin engagement induces the phosphorylation of the
Src kinase Fgr and the ITAM (immunoreceptor tyrosine-based
activation motif)-containing adaptor proteins DAP12 and FcRγ
(Zarbock et al., 2008a; Yago et al., 2010). DAP12 and FcRγ subse-
quently recruit and activate the tyrosine kinase Syk (Zarbock et al.,
2008a). In neutrophils from Fgr−/− mice and Lyn−/−/Hck−/−
mice, DAP12, and Syk phosphorylation does not occur follow-
ing E-selectin engagement (Zarbock et al., 2008a). In this signaling
pathway, SLP-76 and the Tec family kinase Bruton’s tyrosine kinase
(Btk) are located downstream of Syk, whereas the signaling path-
way downstream of Btk divides into a phosphoinositide 3-kinase
(PI3K)γ- and PLCγ2-dependent pathway (Mueller et al., 2010;
Block et al., 2012). Following E-selectin engagement the small
GTPase Rap1 is activated downstream of PLCγ2 (Stadtmann et al.,
2011). CalDAG-GEFI (Rasgrp2) and p38 MAPK are crucial sig-
naling molecules between PLCγ2 and Rap1a (Stadtmann et al.,
2011).
During rolling, leukocytes are exposed to different chemokines
and chemoattractants presented on inflamed endothelial cells.
Binding of chemokines to their receptors on leukocytes activates
complex intracellular signaling networks which modulate integrin
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activation and eventually lead to leukocyte adhesion mediated by
binding of leukocyte integrins to their counter-receptors expressed
on the endothelial cell surface.
Chemokine receptors are specific G protein-coupled recep-
tors (GPCRs) on the cell surface and form specific subgroups
depending on the binding capacities for members of distinct
chemokine families. Chemokines are subdivided into different
families depending on their structure characterized by the rela-
tive position of the first two cysteine residues of the chemokine
representing the determining factor for the chemokine family
classification (Baggiolini et al., 1994). For chemokines of the CC-
chemokine family, the first two cysteines are adjacent to each other,
whereas the first two cysteines in CXC chemokines are separated
by one amino acid. Two chemokines are described so far showing
a different positioning of their cysteines. Lymphotactin is charac-
terized by the occurrence of only two cysteines and in fractalkine,
the first two cysteines are separated by three amino acids (CX3C;
Kelner et al., 1994; Bazan et al., 1997). Until now, 10 receptors
for CC-chemokines (CC-chemokine receptors, CCRs), seven for
CXC chemokines (CXC chemokine receptors, CXCRs), and one
CX3C chemokine receptor (CX3CR) are described (Murphy, 2002;
Burns et al., 2006). Chemokine receptors on the cell surface of neu-
trophils are exposed to different chemokines during rolling on the
inflamed endothelium. Following binding of the chemokine to its
receptor, intracellular signaling cascades are activated resulting in
integrin activation (Zarbock et al., 2012). Neutrophils express dif-
ferent chemokine receptors on their surface, like CXCR1, CXCR4,
CCR2, and CX3CR1, but for CXCR2 many different important
functions are described. CXCR2 was cloned for the first time in
1991 from the human cell line HL-60 (Murphy and Tiffany, 1991).
High affinity ligands for CXCR2, which is also expressed on other
immune cells like mast cells, monocytes, and macrophages, are
CXCL1, 2, 3, 5, 6, 7, and 8 (Olson and Ley, 2002). The most potent
ligand of CXCR2 is CXCL8 as well as cleavage products of this
chemokine (Van Damme et al., 1989). CXCL8 was first described
and characterized as a product with chemotactic characteristics in
the supernatant of LPS-stimulated human mononuclear cells in
1988 (Matsushima et al., 1988).
There is an important difference between human and murine
neutrophils concerning chemokine receptor expression on the
surface of neutrophils. Human neutrophils express CXCR1 and
CXCR2, whereas murine neutrophils only express CXCR2, even
if there are some recent reports about murine CXCR1 homologs
(Fu et al., 2005; Moepps et al., 2006). High affinity ligands of
CXCR1 are CXCL6 and 8 (Wolf et al., 1998). CXCL8 is the major
CXCR2 ligand in humans, but in some cases, CXCL8 also binds to
and mediates some functions via CXCR1. Rodents do not express
CXCL8 (Reutershan, 2006).
Following adhesion, integrins may activate different signaling
pathways that regulate several cellular functions including cell
motility, polarization, respiratory burst, phagocytosis, prolifera-
tion, and apoptosis (Abram and Lowell, 2007). Integrin clustering
and ligand-induced allosteric conformational changes likely initi-
ate outside-in signaling and signalosome formation. The efficient
protein tyrosine kinase (PTK) recruitment and activation of vari-
ous signaling pathways require the formation of signalosomes (Ley
et al., 2007). The two Src family kinase members Hck and Fgr are
required for transducing LFA-1- and Mac-1-mediated outside-in
signaling (Giagulli et al., 2006). However, these two Src family
kinases are not required for chemoattractant-triggered upregula-
tion of LFA-1 affinity and leukocyte arrest (Giagulli et al., 2006).
Leukocyte adhesion strengthening can be abolished by blocking
β2-integrin-mediated outside-in signaling (Giagulli et al., 2006).
Additionally, by eliminating WASP (Sato et al., 2012), the GEFs
VAV1 and VAV3 (Gakidis et al., 2004), or PI3Kγ (Smith et al.,
2006) representing important signaling molecules of leukocytes,
adhesion strengthening can be blocked.
CHEMOKINE RECEPTORS ARE CHARACTERIZED BY
DISTINCT STRUCTURAL PROPERTIES
Chemokine receptors are normally composed of 340–370 amino
acids and show a 25–80% amino acid homology (Olson and Ley,
2002). GPCRs are seven-transmembrane proteins and consist of
an α-subunit and a βγ-complex whereas the classification of these
receptors depends on their α-subunit. Neutrophils express Gs-,
Gi-, and Gq-family members with Gi-proteins representing the
most important G proteins on neutrophils. This subclass medi-
ates almost all pro-inflammatory effects of chemoattractants and
can be subdivided into different subunits (Gαz, Gαo, Gαi1, Gαi2,
and Gαi3; Wilkie et al., 1992). With pertussis toxin (PTx), Gαi-
signaling with the exception of Gαz-signaling can be blocked.
Leukocytes abundantly express Gαi2 and Gαi3 (Jiang et al., 2002).
A study by Zarbock et al. (2007a) demonstrated an important role
for Gαi2 for chemokine-induced neutrophil arrest in in vitro and
in vivo models. A study using Gαi2 deficient mice showed that
Gαi2 in non-hematopoietic cells is involved in leukocyte migra-
tion into the lung in an allergy model and after LPS application,
whereas Gαi2 in leukocytes is involved in regulating chemotaxis
in response to chemokines (Pero et al., 2007). Gαi3 regulates
neutrophil migration via GIV (Gα− interacting vesicle-associated
protein; Ghosh et al., 2008), redistributes and localizes at the lead-
ing edge of the cell during the cell migration process (Ghosh et al.,
2008). A number of Gβγ-complexes can be formed, due to the fact
that leukocytes express five different β-subunits and 12 γ-subunits
(Wettschureck and Offermanns, 2005).
Chemokine receptors are special GPCRs and share some struc-
tural characteristics like an NH2-terminal domain which is part of
the chemokine binding site (Olson and Ley, 2002). They also have
a conserved sequence in the second intracellular loop consisting
of 10 amino acids (Olson and Ley, 2002) and share a character-
istic cysteine within each extracellular domain and a short basic
third intracellular loop (Murphy et al., 2000). The N-terminus of
chemokine receptors which is characterized by a tyrosine sulfa-
tion motif (Murphy et al., 2000) is not important for the ligand
binding affinity, however this domain is important for receptor
triggering (Murphy et al., 2000). Recent studies made remarkable
progress in the reconstruction of secondary and tertiary structures
of GPCRs. Specialized methods like X-ray crystallography and
electron microscopy revealed new insights into GPCR structures
(Unger and Schertler, 1995; Pebay-Peyroula et al., 1997).
CXCR1 and CXCR2 are both Gαi-coupled proteins and 78%
of their amino acid sequences are identical (Reutershan, 2006).
Divergent regions carrying the differences between the two recep-
tors are the N-terminus, the C-terminus, the second extracellular
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loop, and the fourth transmembrane domain (Nasser et al., 2007).
These regions are probably responsible for functional differences
between CXCR1 and CXCR2 which will be mentioned later on.
CXCR2 is a member of the rhodopsin-like family of GPCRs, how-
ever the crystal structure of CXCR2 is not revealed, yet (Murphy
et al., 2000).
GPCR-INDUCED SIGNALING
Binding of a chemokine to its receptor may induce many dif-
ferent cellular responses like adhesion, migration, and chemo-
taxis including cellular shape changes, reorganization of the actin
cytoskeleton, upregulation of integrin expression, and integrin
activation (Baggiolini, 1998).
The activation of a GPCR by the engagement of a chemoat-
tractant results in an activation of the associated G protein, which
dissociates into the GTP-bound Gα-subunit and the Gβγ-complex
(Zarbock and Ley, 2008). Both, the α-subunit and the βγ-complex,
are able to activate different signaling molecules (Figure 1).
Following dissociation, the α-subunit inhibits some adenylyl
cyclase isoforms leading to a decrease of intracellular cAMP-
levels and cAMP-dependent protein kinase activity (Sunahara
et al., 1996). Gαi-subunits are also involved in the activation
of small GTPases following GPCR activation. Gαi-dependent
Ras activation induces the activation of phosphatidylinositol-3-
kinase (PI3K) by directly binding to the catalytic subunit of PI3K
(Rodriguez-Viciana et al., 1994).
The βγ-complex is able to activate PI3Kγ and the two phospho-
lipase C (PLC) isoforms β2 and β3 (Camps et al., 1992; Hirsch et al.,
2000). PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate to
generate inositol trisphosphate (IP3), which mobilizes calcium
from non-mitochondrial stores, and diacylglycerol (DAG), which
activates Ca2+-independent and Ca2+-dependent protein kinase
C (PKC; Berridge and Irvine, 1984). Different PKC isoenzymes
are required for activating cytotoxic effector functions of neu-
trophils (Mayer et al., 1996). PLC β2-deficient neutrophils show
enhanced chemotaxis and increased leukocyte recruitment in
FIGURE 1 | General model of chemokine-induced signaling.
Downstream of the α and βγ subunits, different signaling molecules are
activated leading to different cellular functions. AC, adenylyl cyclase; Akt,
proteine kinase B; Ca2+, calcium; cAMP, cyclic adenine monophosphate;
DAG, diacylglycerol; GEFs, guanine exchange factors; GPCR, G protein
coupled receptor; IP3, inositol triphosphate; PI3K, phosphatidylinositol-
3-kinase; PKC, protein kinase C; PLCβ, phospholipase C beta; Rho, Ras,
Rap1, small G proteins.
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response to fMet-Leu-Phe (fMLP), but reduced chemoattractant-
induced Ca2+ release and macrophage-1 antigen (Mac-1) upreg-
ulation (Jiang et al., 1997). Murine neutrophils deficient in both,
PLC β2 and PLC β3, show impaired chemokine-stimulated O2−
formation (Li et al., 2000). It has also been shown that PLC
is involved in chemokine-induced α4β1-integrin activation and
monocyte adhesion (Hyduk et al., 2007). A recent study by Stadt-
mann et al. (2011) demonstrated that the GEF CalDAG-GEFI,
which requires Ca2+ and DAG for activation, is necessary for
chemokine-induced neutrophil arrest in vivo.
PI3Kγ, which can be activated by different βγ-subunits,
catalyzes the phosphorylation of phosphatidylinositol-3,4-
bisphosphate (PIP2) to phosphatidylinositol-3,4,5-trisphosphate
(PIP3) which is able to bind to proteins containing pleckstrin
homology domains, leading to downstream signaling (Varnai et al.,
1999). Such an example for PI(3)Kγ-dependent downstream sig-
naling is the activation of Akt, which clusters at the leading edge
of migrating neutrophils (Figure 1; Servant et al., 2000).
The small GTPases of the Rho-family are also activated down-
stream of PI3Kγ (Servant et al., 2000). Neutrophils express Rac1
and Rac2 and both molecules regulate the migration of neu-
trophils, whereas Rac2 is also involved in the regulation of the
respiratory burst (Glogauer et al., 2003; Gu et al., 2003). The
activation of Rac is mediated by guanine nucleotide exchange
factors (GEFs) by exchanging GDP for GTP. Different GEFs are
expressed in neutrophils and these molecules are involved in Rac
activation like the GEFs of the P-Rex family which are directly acti-
vated by the Gβγ subunit and PIP3. In contrast, Vav family GEFs
in neutrophils are activated in a Syk and Src kinases dependent
pathway (Figure 1; Welch et al., 2002; Fumagalli et al., 2007). A
recent study by Lawson et al. (2011) demonstrated that P-Rex-1-
and Vav-1-deficiency mediates severe defects in GPCR depen-
dent neutrophil activation. Another important molecule called
DOCK2 (dedicator of cytokinesis 2), can also regulate the activ-
ity of Rac1 and Rac2 (Kunisaki et al., 2006) and influences cell
polarity changes and translocation speed (Kunisaki et al., 2006).
Activated Rac activates p21-activated kinase (PAK), which can
subsequently induce the phosphorylation of extracellular signal-
regulated kinase 1/2 (ERK1/2), p38 mitogen-activated protein
kinase, and c-Jun N-terminal kinase (Kim and Dinauer, 2001;
Fumagalli et al., 2007).
CXCR2-triggered signaling uses the same molecules described
above, but a recent study by Wu et al. (2012) revealed a new mech-
anism for the coupling of CXCR2 to its downstream signaling
molecules. They showed that the PDZ scaffold protein Na+/H+
exchanger regulatory factor-1 (NHERF1) couples CXCR2 to its
downstream effector PLC-β2, forming a macromolecular complex,
through a PDZ-based interaction (Wu et al., 2012). Disruption of
this complex led to a decrease of intracellular calcium concentra-
tions on the molecular level, and suppressed neutrophil chemo-
taxis and migration on the cellular level following chemokine
stimulation (Wu et al., 2012).
There are differences described for the signaling cascades down-
stream of either CXCR1 or CXCR2 activation. In contrast to
CXCR2 dependent signaling, phospholipase D gets activated and
neutrophils are primed to perform respiratory burst following
CXCR1 activation (L’Heureux et al., 1995; Jones et al., 1996). Due
to these data, it is likely that the activation of the two receptors
play different roles under inflammatory conditions.
CXCR2 IS INVOLVED IN PHYSIOLOGICAL AND
PATHOLOGICAL CONDITIONS
Neutrophils are essential for maintaining innate immune surveil-
lance under normal conditions, but also represent a major contrib-
utor to tissue damage during autoimmune processes. Therefore,
neutrophil homeostasis and recruitment are tightly regulated.
CXCR2 plays a critical role in the regulation of neutrophil home-
ostasis (Eash et al., 2010; von Vietinghoff et al., 2010; Mei et al.,
2012), because CXCR2-deficient mice demonstrate mild neu-
trophilia and severe neutrophil hyperplasia in the bone marrow
(Shuster et al., 1995). A recent study demonstrated that CXCR2-
signaling is a second chemokine axis that interacts antagonistically
with CXCR4 to regulate neutrophil release from the bone marrow
(Eash et al., 2010).
During inflammation, leukocyte extravasation from the blood
vessel into inflamed tissue is one of the hallmarks of the immune
system. However, leukocyte recruitment has to be tightly regulated,
as excessive leukocyte extravasation may lead to the deteriora-
tion of the integrity of the organism and may worsen acute and
chronic inflammatory diseases. Different chemokines, which are
released during inflammation, direct leukocytes to the site of
inflammation. The chemokine receptor CXCR2 and its ligands
have been implicated in a variety of inflammatory disorders mak-
ing it an interesting target for therapeutical approaches (Seitz
et al., 1991; Boyle Jr. et al., 1998; Kurdowska et al., 2001; Biz-
zarri et al., 2006; Reutershan, 2006; Chapman et al., 2009). In
several inflammatory disease models, blocking, or eliminating
CXCR2 substantially reduces leukocyte recruitment, tissue dam-
age, and mortality. Based on the physiological importance of
CXCR2, selective CXCR2 inhibitors have been developed that
are now being tested in clinical trials. Due to the structural
similarities between CXCR1 and CXCR2 or an influence by the
activity of one of these receptors on the activity of the other,
CXCR2 manipulation may affect CXCR1 dependent functions.
This possibility has to be tightly controlled, but experiments
in the murine system do not include these cross-reactivities
because murine neutrophils do not express CXCR1. The following
part summarizes current knowledge about CXCR2 in inflam-
matory diseases and discusses its potential as a pharmaceutical
target.
LUNG DISEASES
CXCR2 is found on many cells including leukocytes, endothelial,
and epithelial cells. On endothelial cells, CXCR2 expression was
demonstrated for the human and murine system (Murdoch et al.,
1999; Addison et al., 2000). Additionally it was demonstrated that
CXCR2 expression is important for angiogenesis and supports
tumor growth (Addison et al., 2000; Keane et al., 2004). Lung
epithelium of COPD patients expresses elevated levels of CXCR2,
but not CXCR1, indicating different roles for these two receptors
under COPD disease conditions (de Boer, 2002; Qiu et al., 2003).
Due to its expression on lung endothelial and epithelial cells,
it is not surprising that CXCR2 has been implicated in different
lung diseases. Several studies have identified an important role
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for CXCR2 in acute lung injury (ALI), asthma, COPD, and cystic
fibrosis (CF).
ACUTE LUNG INJURY
Acute lung injury is characterized by a damage of the alveolar-
capillary barrier resulting in infiltration of neutrophils into the
lungs, pulmonary edema, remodeling of the alveolar and small air-
way epithelium, and collagen deposition in the pulmonary inter-
stitium. Lung fibrosis can result from ALI (Ley and Zarbock, 2008;
Chapman et al., 2009). ALI may completely resolve or proceed to
fibrosing alveolitis accompanied by persistent low oxygen in the
blood (hypoxemia) and a reduced ability of the lung to expand
with every breath (reduced pulmonary compliance; Rubenfeld
et al., 2005). In both pulmonary diseases, a functional role for
CXCR2 has been implicated.
Acute lung injury is a common disease with an incidence of 79
per 100,000 person-years in the United States (Rubenfeld et al.,
2005). Despite the use of state-of-the-art treatment, this disease
is associated with high mortality of up to 38% (Rubenfeld et al.,
2005). Pneumonia and acid aspiration are intrapulmonary causes
of ALI whereas trauma, massive transfusion, and sepsis are typ-
ical causes of extrapulmonary ALI. During ALI, neutrophils are
recruited in the alveolar compartment and increased CXCL8 lev-
els in the BAL fluid of patients with ALI have been positively
correlated with the presence of activated neutrophils (Aggarwal
et al., 2000; Kurdowska et al., 2001; Keane et al., 2002; Puneet et al.,
2005). High levels of CXCL8 complexed with anti-CXCL8 autoan-
tibodies were found in the alveolar fluid of patients suffering from
ALI (Fudala et al., 2007). As these complexes can inhibit neutrophil
apoptosis (Fudala et al., 2007), it is possible that this condition may
prolong neutrophil survival and exacerbate the deleterious effects
of neutrophil activation. These data identify CXCL8 as an impor-
tant chemokine in the pathogenesis of ALI (Puneet et al., 2005).
In addition to this, CXCL8 has also been associated with other
pathophysiological aspects of ALI. Due to an increase in vascu-
lar permeability, higher levels of α2 macroglobulin, and CXCL2
are found in the BAL of of patients with ALI (Kurdowska et al.,
1997). CXCL8 andα2 macroglobulin form complexes which main-
tain chemoattractant activity (Kurdowska et al., 2001). Based on
this fact, it is likely that the complex perpetuates the inflamma-
tory response in the lungs of ALI patients. Patients with CXCL8
gene polymorphisms accompanied with higher levels of CXCL8
have more prolonged and extensive lung injury which requires an
extended time on ventilatory support (Hildebrand et al., 2007).
In animal models of ALI, a very important role for CXCL8
and CXCR2 has been clearly identified. Exposure to hyperoxic gas
(Sue et al., 2004) and ventilator-induced lung injury (Strieter et al.,
2005b) caused neutrophil recruitment into the lung, increased air-
way microvascular leakage, and induced lung edema. Each of these
pathological changes was diminished in WT animals treated with
neutralizing antibodies to CXCR2 or in CXCR2-deficient mice.
Similar findings were observed following blocking CXCR2 in ani-
mal models of lung injury induced by lipopolysaccharide (LPS;
Chapman et al., 2007), after lung infection with viral or bacterial
challenge (Tsai et al., 2000; Del et al., 2001; Londhe et al., 2005b;
Strieter et al., 2005a) and after induction of hemorrhagic shock
(Lomas-Neira et al., 2004).
Angiogenesis is considered to be an important component of
collagen deposition and fibrosis formation in the lungs (Keane
et al., 2004). A variety of CXC chemokines possessing angiogenic
properties are expressed in pulmonary edema fluid of patients
with ALI (Keane et al., 2002) with CXCR2 as an important recep-
tor mediating this effect (Addison et al., 2000). These data suggest
that inhibition of CXCR2 may also be beneficial in reducing the
development of pulmonary fibrosis in ALI patients.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Chronic obstructive pulmonary disease (COPD) is characterized
by a limitation of the airflow that is not fully reversible, and is usu-
ally progressive with an abnormal inflammatory response (Rabe
et al., 2007). This disease is primarily caused by cigarette smoking
where recurrent lung infections may induce a progressive decline
in lung function. Small airway disease (obstructive bronchiolitis)
and parenchymal destruction (emphysema) are the causes of the
limited airflow. Bacterial and viral infections are frequent causes
of COPD exacerbations. No medication exists that prevents the
long-term decline in lung function, however at the present time,
inhaled anticholinergics, β-adrenergic bronchodilators, and cor-
ticosteroids are used to treat the symptoms and exacerbations of
COPD.
Chronic bronchitis is associated with excess mucus secretions
in the large airways and a large number of recruited leukocytes,
especially neutrophils (de Boer et al., 2000; Rabe et al., 2007). As
chronic bronchitis is associated with mucus hypersecretion and
neutrophil recruitment, it is not surprising that CXC chemokines
and CXCR2 expression in the bronchial biopsies and sputum of
COPD patients are increased (Traves et al., 2002; Qiu et al., 2003).
Animal studies using lung infection models demonstrated that
CXCR2 has an important role in this response (Tsai et al., 2000;
Del et al., 2001; Miller et al., 2003; Londhe et al., 2005a). Sim-
ilar observations can be made in humans suffering from COPD.
Increased CXCR2 mRNA expression is present in bronchial biopsy
specimens from COPD patients which goes along with the pres-
ence of tissue neutrophils during severe exacerbations of COPD
(Qiu et al., 2003). These data suggest that CXCR2 inhibition may
be a viable therapeutic approach against the inflammatory events
occurring in the distal lungs of human COPD patients.
In contrast to the mucus hypersecretion in the large conduct-
ing airways, the presence of inflammatory mucus exudates in the
peripheral airways contributes significantly to the airflow obstruc-
tion in COPD (Hogg et al., 2004). In animal studies using different
COPD models, blocking CXCR2 inhibited mucus hypersecretion,
and goblet cell hyperplasia (Miller et al., 2003; Stevenson et al.,
2005; Chapman et al., 2007). However, these animal models inves-
tigated the mucus production in the large conducting airways,
where the mucus rarely leads to airflow obstruction. Therefore, it
will be important to assess the effect of CXCR2 blockade on mucus
inflammatory exudates and obstruction in the peripheral airways.
ASTHMA
Asthma is a common chronic inflammatory disease of the
airways characterized by variable and recurring symptoms,
reversible airflow obstruction, bronchial hyperresponsiveness,
chronic eosinophilic lung inflammation, and bronchospasm
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(Bousquet et al., 2000). Symptoms include coughing, wheezing,
chest tightness, and shortness of breath (Bousquet et al., 2000).
Mild to moderate asthma is treated with a combination of inhaled
beta-adrenergic bronchodilators and corticosteroids. However,
severe asthmatics only respond poorly to inhaled beta-adrenergic
agonists and corticosteroids. Severe asthma is characterized by a
predominantly neutrophilic inflammation of the lung with airway
remodeling.
During severe asthma, a positive correlation between increased
expression of ELR+ CXC chemokines, which carry the Glu-Leu-
Arg (ELR) tripeptide motif at the NH2-terminus, and the presence
of neutrophils in the lung exists (Kurashima et al., 1996; Lamblin
et al., 1998; Norzila et al., 2000; Pease and Sabroe, 2002; Mukaida,
2003). In addition, it has been shown that increases in sputum
CXCL8 precede the exacerbations of acute asthma (Mukaida,
2003). Viral and bacterial lung infections contribute significantly
to the frequency of asthma exacerbations and studies in animals
have shown an important role for CXCR2 in this response.
Eosinophils are present in sputum and bronchial biopsies of
patients with mild to moderate asthma. Under physiological con-
ditions, the expression and role of CXCR2 on eosinophils is uncer-
tain. However, it is possible that this receptor plays a role on these
cells under conditions of chronic lung inflammation. Given the
fact that CXCR2 is highly expressed on the vascular endothelium
and that animal studies have demonstrated a role for endothelial
CXCR2 on mast cell migration into tissue following sensitization
to allergen (Hillyer et al., 2003; Abonia et al., 2005; Hallgren et al.,
2007), this may be important in inducing acute phase responses
to allergen challenge.
The increased formation of blood vessels in airway mucosa with
associated changes in the vascularity is a characteristic of human
asthma (McDonald, 2001; Hashimoto et al., 2005). Th2-dependent
cytokines induce the synthesis of angiogenic chemokines (Mat-
suda et al., 2008), and different studies demonstrated that CXCR2
and its ligands are involved in the formation of new blood ves-
sels in the lungs (Addison et al., 2000; Belperio et al., 2000; Babu
et al., 2007; Mohsenin et al., 2007). CXCR2 is also expressed on air-
way smooth muscles and it could be speculated that the receptor
is involved in the contractile and migratory responses of airway
smooth muscle in chronic asthma (Govindaraju et al., 2006).
This also raises the possibility that CXCR2 on airway smooth
muscle cells is involved in the development of bronchial hyper-
responsiveness in asthmatics. Indeed, inhalation of CXCL8 causes
bronchoconstriction in pigs (Fujimura et al., 1999).
These data identify an important role for the CXC chemokines
and CXCR2 in lung inflammation, lung histopathology, and
abnormal physiology that is seen in asthma.
CYSTIC FIBROSIS
Cystic fibrosis is an autosomal genetic disease affecting most
critically the lungs, and also the pancreas, intestine, and liver.
CF is caused by a mutation in the gene for the protein CF
transmembrane conductance regulator (CFTR) and the disease
is characterized by abnormal transport of chloride and sodium
across epithelium, leading to thick, viscous secretions (Clunes and
Boucher, 2007). The absence or lack of functional CFTR in the air-
way epithelium leads to dysfunctional lung mucociliary clearance,
recurrent lung infections, hypertrophy and hyperplasia of mucus
secreting cells and glands, and small airway obstruction. The air-
ways of patients suffering from CF are frequently infected with
bacterial pathogens, which determine morbidity and mortality in
these patients (Chapman et al., 2009). As a consequence of the
airway infection, pro-inflammatory cytokines, and chemokines,
including CXCL8, are produced that attract large numbers of
neutrophils into the lung (Dean et al., 1993; Elizur et al., 2008).
However, it is very likely that a variety of chemokines are involved
in the pathology of CF as several non-ELR+ CXC chemokines
are also known to play a role in the inflammatory process of CF
(Mackerness et al., 2008).
In CF patients, high levels of neutrophil elastase are found
in airway secretions (Goldstein and Doring, 1986) which prob-
ably participates in the elevated mucus secretion in these patients
(Voynow et al., 2004; Tirouvanziam et al., 2008). Studies of dif-
ferent animal models indicated that CXCR2 is involved in mucus
hypersecretion and proliferation of mucus secreting cells in the air-
way. Neutrophils are also important for the antimicrobial response
of the lungs (Tsai et al., 2000; Hartl et al., 2007). However, recently
published studies suggest that CXCR1 rather than CXCR2 is the
functionally important receptor involved in neutrophil degran-
ulation (Geiser et al., 1993; Jones et al., 1996; Patel et al., 2001;
Feniger-Barish et al., 2003). Therefore, blocking CXCR2 should
not affect neutrophil phagocytosis and mediator release. As there
is evidence showing the cleavage of CXCR1 on neutrophils, which
disables the bacterial-killing capacity of neutrophils from CF
patients (Hartl et al., 2007), the incidence of infection should be
closely monitored.
SEPSIS
Sepsis is a major healthcare problem, affecting millions of indi-
viduals around the world each year, killing one in four, and
increasing in incidence (Dombrovskiy et al., 2007; Andaluz-Ojeda
et al., 2011). The immune system combats microbial infections
but, in severe sepsis, its untoward activity seems to contribute
to organ dysfunction. The inappropriate activation and position-
ing of neutrophils within the microvasculature contributes to the
pathological manifestations of multiple organ failure.
Cummings et al. (1999) showed that the expression levels of
CXCR2 on circulating neutrophils of septic patients are decreased
by approximately 50% in comparison to control donors. This was
associated with a reduced migratory activity of neutrophils toward
ligands specifically binding to CXCR2 (CXCL1-3 and CXCL5),
while migration toward IL-8 was unaffected (Cummings et al.,
1999). The expression level of CXCR1 did not show any signifi-
cant alterations, suggesting an important role of CXCR1 in septic
patients (Cummings et al., 1999). CXCR2 downregulation can
be explained by the high levels of soluble chemokines circulat-
ing within the plasma of septic patients (Phillipson and Kubes,
2011).
While CXCR2 is important for leukocyte extravasation into
inflamed tissue and might be highly relevant for bacterial clear-
ance and survival in bacteria-induced pulmonary inflamma-
tion, it has deleterious effects in sepsis. Blocking or eliminating
CXCR2 decreased liver injury and mortality in a murine model
of cecal ligation and puncture (CLP)-induced sepsis (Ness et al.,
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2003). Although neutrophil recruitment into the peritoneum
was delayed, bacterial clearance was not affected by eliminating
CXCR2. Application of cell-penetrating lipopeptides, which block
CXCR1- and CXCR2-signaling, reversed the lethal sequelae of sep-
sis, including multi-organ failure and disseminated intravascular
coagulation in mice, indicating that CXCR2 is very important in
sepsis (Kaneider et al., 2005).
REPERFUSION-INJURY
Ischemia-reperfusion-injury contributes to morbidity and mor-
tality in a wide range of pathologies, including circulatory arrest,
ischemic stroke, myocardial infarction, acute kidney injury, and
trauma. Additionally, it is a common challenge during cardiotho-
racic and vascular surgery and organ transplantation. Due to the
reduced metabolic supply in the ischemic organ, tissue hypoxia,
and microvascular dysfunction occur. The subsequent reperfusion
activates an innate and adaptive immune response (Eltzschig and
Eckle, 2011) with a characteristic strong accumulation of inflam-
matory cells, predominantly neutrophils, into the injured organs
leading to tissue injury (Eltzschig and Eckle, 2011).
Since neutrophil infiltration is a major cause of tissue injury,
mechanisms involved in neutrophil recruitment following an
inflammatory stimulus are interesting targets for therapeutic
approaches. Several recent studies demonstrated a positive effect
of inhibiting neutrophil recruitment into the region of ischemia-
reperfusion (Kempf et al., 2011; Block et al., 2012).
Neutrophil depletion reduces tissue injury after myocardial
ischemia-reperfusion in patients (Palatianos et al., 2004) and
animals (Litt et al., 1989). In a model of myocardial infarc-
tion, Tarzami et al. (2003) demonstrated that the infarct size in
CXCR2-deficient mice is significantly reduced in comparison to
wildtype mice, predominantly mediated by CXCR2 on hematopoi-
etic cells. More precise, investigation of the infarcted zone revealed
a decreased number of infiltrated immune cells in CXCR2−/−mice
(Tarzami et al., 2003). This finding is consistent with the important
role of CXCR2 in leukocyte recruitment into inflamed tissue.
During organ transplantation, reperfusion-injury mediated by
neutrophils is a major challenge, because it is associated with
increased morbidity and mortality (King et al., 2000). Neutrophil
accumulation in the kidney occurs rapidly after reperfusion, is
associated with an increased CXCR2 and CXCL1 expression in the
graft and is an important predictor of delayed graft function after
kidney transplantation (Turunen et al., 2004). Blocking CXCR2
by an inhibitor reduces neutrophil accumulation in the kidney
and maintains kidney function (Cugini et al., 2005). Inhibition of
CXCR2 also reduced neutrophil recruitment and organ dysfunc-
tion in other models of ischemia-reperfusion-injury (Bertini et al.,
2004; Souza et al., 2004; Belperio et al., 2005).
POSSIBLE THERAPEUTIC STRATEGIES BY BLOCKING CXCR2
As described above, CXCR2 and CXCR2 ligands are involved
in many processes which can influence different disease con-
ditions. Therefore, controlling CXCR2 and therewith CXCR2
dependent processes can be powerful therapeutic mechanisms.
Affecting CXCR2 dependent pathways is possible in different ways.
Distinct strategies including N-terminally modified chemokines,
antibodies, and small-molecule antagonists were tested.
Several low molecular weight CXCR2 antagonists have been
developed and tested in different in vitro and in vivo models. The
first low molecular weight CXCR2 antagonist was described in
1998 in a study by White et al. (1998). The described antagonist was
a selective non-peptide antagonist of CXCR2 and inhibited CXCL8
and GROα dependent neutrophil chemotaxis in vitro. Therefore, it
was suggested as a potential tool for therapeutic application (White
et al., 1998). Following the identification of this compound, a class
of diarylureas was tested in different disease models for possible
therapeutic usage.
Another type of CXCR2 inhibitors are allosteric inhibitors,
which block CXCR2 function by blocking receptor signaling
instead of chemokine binding. In the beginning of allosteric
inhibitor investigation, a concentration-dependent inhibitory
effect on CXCL8 function, such as neutrophil chemotaxis was
reported (Souza et al., 2004). Non-steroidal anti-inflammatory
drugs known as ketoprofen and ibuprofen were reported to be
potent inhibitors of CXCL8 dependent neutrophil chemotaxis
(Bizzarri et al., 2001). Subsequently, a series of potent allosteric
CXCR2 inhibitors were described. Another non-competitive
allosteric inhibitor is Reparixin (or Repertaxin), which specifi-
cally blocks CXCR1 or CXCR2-mediated neutrophil migration
in vitro without affecting other receptors (Bertini et al., 2004).
It was previously demonstrated that Reparixin inhibits CXCL8
induced neutrophil activation and blocks the increase of intra-
cellular free calcium, elastase release, and production of reactive
oxygen intermediates (Bertini et al., 2004). The application of this
inhibitor in different disease models demonstrated that Repar-
ixin is able to mediate beneficial effects in a bacteria-induced
peritonitis, a venom-induced lung injury, and different models
of ischemia-reperfusion-injury (Bertini et al., 2004; Souza et al.,
2004; Cugini et al., 2005; Garau et al., 2005; Coelho et al., 2007). A
recently published study by Zarbock et al. (2008b) demonstrated
that Reparixin attenuates ALI by reducing neutrophil recruitment
and vascular permeability. Because of suboptimal pharmacoki-
netic characteristics of Reparixin, related compounds were tested
and DF 2162 was reported to have similar effects as Reparixin, but
better pharmacokinetic characteristics (Coelho et al., 2007; Cunha
et al., 2008; Chapman et al., 2009).
The pyrimidine series-based CXCR2 antagonist AZD-8309 has
been clinically tested in different disease models. A recent report by
Virtala et al. (2011) reported that AZD-8309 application reduced
LPS-induced neutrophil recruitment and elastase activity about
50% in comparison to placebo application in a lower airway LPS
model.
Different CXCR2 antagonists developed by GlaxoSmithKline
were also reported to be able to inhibit chemokine binding to
CXCR2, mediating decreased migration in response to CXCL1, 5,
and 7 (Traves et al., 2004). Another antagonist was demonstrated
to inhibit CD11b upregulation and shape changes as characteris-
tics of neutrophil activation following stimulation with CXCL1 of
neutrophils from COPD patients (Chapman et al., 2009). One of
the antagonists of this group, SB-656933, was already tested in clin-
ical trials of CF and ozone-induced tissue injury. In this study, oral
administration of SB-656933 inhibited CXCL1-induced CD11b
upregulation on neutrophils and reduced ozone-induced airway
inflammation in a dose-dependent manner. This was quantified
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by neutrophil counts in the sputum following ozone challenge
(Lazaar et al., 2011).
Another recent study reported that the CXCR2 antagonist
SCH527123, which is a potent inhibitor of neutrophil activation
and trafficking in animal models, is a potent inhibitor of ozone-
induced neutrophil recruitment in a human clinical trial (Holz
et al., 2010). SCH527123 treatment of healthy humans resulted
in significantly lower sputum total cell and neutrophil counts as
well as CXCL8 levels following ozone treatment in comparison
to prednisolon or placebo treated study participants (Holz et al.,
2010).
GSK1325756, a specifically designed CXCR2 antagonist, was
already tested in a phase I clinical trial, determining the effects of
GSK1325756 in healthy adult volunteers (www.clinicaltrials.gov,
study number NCT01267006). In this study, blood parameters
were checked in participants treated with either a placebo or
GSK1325756. In another group the effect of food to the levels
and outcome of GSK1325756 was investigated.
As CXCR2 is involved in the pathogenesis of many diseases,
this receptor and its ligands are interesting targets for clinical
trials. However, it has to be kept in mind that blocking CXCR2
can have beneficial but also harmful effects. Blocking CXCR2
inhibits the inflammatory response. Following bacterial or viral
infections, the inhibition of the immune response can be very
dangerous. Pathogens cannot be eliminated accurately, leading to
dissemination of the pathogen and systemic infection. On the
other hand, under sterile inflammatory conditions, for example
following ischemia-reperfusion-injury, decreasing the neutrophil
recruitment and the immune response can be beneficial. Further
studies and clinical trials are necessary to further elucidate the
exact effects of blocking CXCR2 and/or its ligands under different
disease conditions.
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